Trametinib is a cancer drug. It is a MEK inhibitor drug with anti-cancer activity.It inhibits MEK1 and MEK2. Trametinib had good results for metastatic melanoma carrying the BRAF V600E mutation in a phase III clinical trial.
Share ThisFacebookTwitterWhatsAppPinterestShare This
Reviews
There are no reviews yet.